Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Glycopyrronium bromide, Placebo to glycopyrronium bromide, Tiotropium; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 1,066 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 75
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more

Conditions: Alzheimer Disease, Mild Cognitive Impairment
Interventions: Placebo, Eligard 22.5Mg Suspension for Injection; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 60 Years to 120 Years · Female only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Boca Raton, Florida • New York, New York • Madison, Wisconsin

Conditions: Hypercholesterolemia, Dyslipidaemias, Obesity
Interventions: GW501516, GW590735; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2004
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Insomnia
Interventions: APD125; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 173 participants
Timeline: 2007
U.S. locations: 1
States / cities: San Diego, California

Conditions: Irritable Colon, Irritable Bowel Syndrome (IBS)
Interventions: GW876008 200mcg, GW876008 20mcg, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Restless Legs Syndrome
Interventions: Pregabalin (Lyrica), Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Aortic Valve Stenosis
Interventions: Ataciguat, Placebo; Drug
Lead sponsor: Jordan D. Miller, Ph.D.; Other
Eligibility: 50 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Inflammation, Overweight
Interventions: Placebo, Palmitoleic acid, 500 mg (Dose 1), Palmitoleic acid, 1,000 mg (Dose 2); Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 80 Years
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Decompensated Heart Failure
Interventions: Lysine Chloride, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Specific Phobia
Interventions: D-cycloserine, Exposure therapy, Placebo; Drug · Behavioral
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Prurigo Nodularis
Interventions: Rocatinlimab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 24
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 18 more

Conditions: Colon Cancer, Precancerous Condition, Rectal Cancer
Interventions: oligofructose-enriched inulin, sulindac, placebo, atorvastatin calcium, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 40 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Drug Dependence
Interventions: 2-4 of the drugs listed below; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Amyotrophic Lateral Sclerosis
Interventions: CK-2017357, Placebo tablets, Riluzole; Drug · Other
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 44
States / cities: Phoenix, Arizona • La Jolla, California • Orange, California + 38 more

Conditions: Coronary Heart Disease, Cardiovascular Disease, Dyslipidemia, Disorder of Cholesterol Metabolism
Interventions: Ezetimibe; Drug
Lead sponsor: Richard E. Ostlund Jr., MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Asthma
Interventions: Placebo, PF-03715455; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more

Conditions: Osteoarthritis, Knee
Interventions: Placebo, CNTX-4975-05; Drug
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 40 Years to 95 Years
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 30
States / cities: Glendale, Arizona • Phoenix, Arizona • Carmichael, California + 23 more

Conditions: Colitis, Ulcerative
Interventions: placebo, MultiStem low dose, MultiStem high dose; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 37
States / cities: San Francisco, California • Lafayette, Colorado • Lakewood, Colorado + 24 more

Conditions: Nearsightedness, Near Sightedness, Near-sightedness
Interventions: SYD-101 0.01%, SYD-101 0.03%, Vehicle; Drug
Lead sponsor: Sydnexis, Inc.; Industry
Eligibility: 3 Years to 14 Years
Enrollment: 852 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 41
States / cities: Irwindale, California • Pasadena, California • San Diego, California + 35 more

Conditions: Neonatal Abstinence Syndrome
Interventions: Clonidine, Placebo; Drug
Lead sponsor: Hennepin County Medical Center, Minneapolis; Other
Eligibility: 36 Weeks to 45 Weeks
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions: KB803, Placebo; Biological · Drug
Lead sponsor: Krystal Biotech, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Rancho Santa Margarita, California • Coral Gables, Florida • Worcester, Massachusetts + 2 more

Conditions: Rheumatoid Arthritis
Interventions: Natrunix, Placebo; Drug
Lead sponsor: XBiotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 26
States / cities: Covina, California • Encino, California • Rancho Mirage, California + 19 more

Conditions: Diabetic Retinopathy
Interventions: Runcaciguat (BAY1101042), Placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Modesto, California • Lakeland, Florida • Pinellas Park, Florida + 6 more

Conditions: Tonsillectomy
Interventions: Celecoxib, Placebo, Acetaminophen, Oxycodone; Drug · Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 3 Years to 11 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation

Safety and Efficacy Study of APD125 in Patient With Insomnia

Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers

Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome

Safety of Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis

Effect of Palmitoleic Acid on C-reactive Protein

Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure

Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics

A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis

Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia

Drug Discrimination in Methadone-Maintained Humans Study 3

Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

Physiological Study of Human Cholesterol Metabolism and Excretion

An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma

A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain

A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis

The Safety and Efficacy of SYD-101 in Children With Myopia

Clonidine as Adjunct to Morphine for Neonatal Abstinence Syndrome

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis

Non-proliferative Diabetic Retinopathy Treated With Runcaciguat

Celecoxib After Tonsillectomy